FIELD: medicine.
SUBSTANCE: invention relates to a method of treating hepatic fibrosis in a patient, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, where R1 is halogen, R2 is C1-6 haloalkyl, R3 is C1-6 alkyl, R4 is hydrogen, and each of A1, A2 is -CH-, and A3 is -N-.
EFFECT: technical result is a novel method of treating hepatic fibrosis, in which hepatic fibrosis is associated with non-alcoholic steatohepatitis (NASH).
6 cl, 6 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS | 2017 |
|
RU2765737C2 |
| HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2800378C1 |
| ISOXAZOLINE AS FATTY ACID AMIDE HYDROLASE INHIBITORS | 2010 |
|
RU2539595C2 |
| CYANOTHIENOTRIAZOLODIAZEPINES AND METHODS FOR THEIR USE | 2016 |
|
RU2750164C2 |
| INHIBITORS - AMINO - CARBOXYMUCONATE - SEMIALDEHYDE - DECARBOXYLASE | 2015 |
|
RU2746405C2 |
| 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | 2014 |
|
RU2675855C2 |
| NEW DRUG FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS AND FIBROSIS | 2017 |
|
RU2762280C2 |
| PHARMACEUTICAL APPLICATION OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUND | 2014 |
|
RU2704257C2 |
| NEUROACTIVE COMPOUNDS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764702C2 |
| 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF THEIR USE | 2014 |
|
RU2812930C2 |
